Sentynl Therapeutics has agreed to license PRG S&T’s investigational molecule, Progerinin (SLC-D011), for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS). The U.S. FDA has already designated Progerinin as an orphan drug. Progeria Defined HGPS or progeroid laminopathies, collectively called progeria, are ultra-rare and fatal genetic premature aging diseases accelerating mortality in young patients. Children who have HGPS typically die of atherosclerosis, a heart disease tha...